New York, US – Feb 13, 2019 – Creative Biolabs, a company that specializes in antibody production and engineering, recently launched its excellent phage display screening services, including in vivo and ex vivo phage display screening services. With years of experience in the field, the company is expected to provide the supreme phage display screening services for its clients around the globe.
Currently, the phage display technology is applied to protein interaction studies, particularly in the discovery of specific antibodies, scaffolds and ligands. Nevertheless, binders with the desired specificity are relatively scarce in the constructed libraries. Against the background, phage display library screening acts as an efficient approach to selecting binders with high affinity and specificity from particular libraries.
The scFv phage library screening services launched by Creative Biolabs include in vivo and ex vivo phage display screening. The former helps specifically isolate the tissue-specific peptides bound to cell markers or cell-penetrating peptides (CPPs). With this strategy, the peptide phage libraries can be directly injected into animals to isolate and identify the phages bound to specific tissues. On the other hand, ex vivo phage display screening is primarily used for discovering peptide and protein ligands for organ- and tissue-specific macromolecules. Both of the two strategies have their unique advantages.
“Compared with other panning approaches, in vivo phage display screening conserves the natural molecular structure and functions of targets in vivo. The phage-displayed peptides isolated by the targets serve as protein transduction domains (PTD) or cell-penetrating peptides (CPPs) for transporting chemotherapeutic agents to the specific tissue, thus improving drug specificity and efficacy in reducing toxicity. Besides, some selected peptides can be used for the functional analysis of new receptors, and the identification and development of new drug target candidates,” a scientist from Creative Biolabs said.
“Ex vivo phage display technology boasts several striking advantages. First, ex vivo phage display can be exposed to all cell types, while in vivo phage display is primarily exposed to the vascular endothelial cells. Second, ex vivo phage display has higher throughput. It’s capable of screening many different phages by using materials from only one mouse. Third, the peptides and ligands isolated by ex vivo phage display can distinguish between the different organs and tissues, and be used as homing devices for therapeutic and imaging agents. Fourth, they can be therapeutics themselves and serve as tools in some medical studies.”
The strengths of in vivo and ex vivo phage display screening include far more than those above mentioned, of course. The strengths are so appealing that there’s every reason to believe that the two services, when appropriately used, will surely promote associated medical project development and help achieve the concerned research purposes.
About Creative Biolabs
Creative Biolabs is a leading custom service provider, boasting rich experience in antibody production and engineering. Its service portfolio includes mouse and rat monoclonal antibody production using hybridoma technology, and human, monkey, rabbit, chicken, dog, llama and camel monoclonal antibody production using various antibody library technologies. In addition, the company also conducts in-depth antibody humanization and affinity maturation.
Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-619-7922Address:45-1 Ramsey Road City: ShirleyState: New YorkCountry: United StatesWebsite: www.creative-biolabs.com/
